Prostate cancer

RTOG 3506

STEEL: A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with PostProstatectomy PSA Recurrences with Aggressive

Topic

S1802

Disease

Prostate cancer

Description

Primary Objective The primary goal of this study is to determine whether, in men with postprostatectomy PSA (prostate specific antigen) recurrences with aggressive disease features, salvage radiotherapy (SRT) with enhanced androgen deprivation therapy (ADT), consisting of enzalutamide (MDV3100) and a GnRH analog, will improve progression-free survival compared to SRT with standard GnRH analog -based ADT.

Contact

Michigan

Maria Pappas

Contact

Florida

Peggy Mouradian

Physicians

Thomas Boike

MD

Radiation Oncologist

Clarkston (Radiation oncology) +3

Larry L. Kestin

MD, FACR, FASTRO

Radiation Oncologist

Farmington Hills (Radiation oncology) +2

Alvaro A. Martinez

MD, FACR, FABS, FASTRO

Radiation Oncologist

Pontiac (Radiation oncology) +4

Frank A. Vicini

MD, FACR, FASTRO, FABS

Radiation Oncologist

Farmington Hills (Radiation oncology) +2

John Vito Antonucci

MD

Radiation Oncologist

Madison Heights (Radiation oncology) +3

Michael I. Ghilezan

MD, PhD

Radiation Oncologist

Pontiac (Radiation oncology) +3

Eduardo B. Fernandez

MD, PhD, DABR, FACRO, FASTRO

Radiation Oncologist

Aventura (Radiation oncology) +3